microdosing glp-1 receptor agonists GLP-1: A Next-Generation Approach to Metabolic and Longevity Medicine: Shamsah Amersi, MD: OB-GYNs Micro-dosing GLP-1 receptor agonists (drugs
Description
To meet demand, both Lilly and Novo look to expand supply capacity of their GLP-1 portfolios
However, the authors did not find any significant association for PTC (MH-OR 1.54, 95% CI 0.773.06
However, their lower-priced options may require multi-month upfront commitments
doi:10.1016/j.neuroscience.2011.02.023 27
doi: 10.1152/japplphysiol.00223.2015
